Literature DB >> 2383977

Antibacterial activity of lomefloxacin against Brucella melitensis.

S M Qadri1, S al-Sedairy, Y Ueno.   

Abstract

The in vitro activity of lomefloxacin was tested against 114 clinical isolates of Brucella melitensis. Comparison was made with ciprofloxacin, tetracycline, gentamicin, rifampin, and trimethoprim-sulfamethoxazole. Lomefloxacin inhibited 113 (99.1%) of the 114 strains tested at less than or equal to 0.5 microgram/ml. It was comparable to ciprofloxacin, tetracycline and gentamicin in antimicrobial potency. One strain that was previously susceptible to ciprofloxacin and had become resistant after the patient was treated with ciprofloxacin showed cross-resistance to lomefloxacin.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2383977     DOI: 10.1016/0732-8893(90)90074-6

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  4 in total

Review 1.  Quinolones for treatment of human brucellosis: critical review of the evidence from microbiological and clinical studies.

Authors:  Matthew E Falagas; Ioannis A Bliziotis
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

2.  In vitro activities of six new fluoroquinolones against Brucella melitensis.

Authors:  I Trujillano-Martín; E García-Sánchez; I M Martínez; M J Fresnadillo; J E García-Sánchez; J A García-Rodríguez
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

3.  Treatment of human brucellosis with doxycycline and gentamicin.

Authors:  J Solera; A Espinosa; E Martínez-Alfaro; L Sánchez; P Geijo; E Navarro; J Escribano; J A Fernández
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

Review 4.  Recognition and optimum treatment of brucellosis.

Authors:  J Solera; E Martínez-Alfaro; A Espinosa
Journal:  Drugs       Date:  1997-02       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.